Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Neumora Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
NMRA
Nasdaq
8731
https://neumoratx.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Neumora Therapeutics Inc
We're Hopeful That Neumora Therapeutics (NASDAQ:NMRA) Will Use Its Cash Wisely
- Apr 24th, 2024 12:14 pm
Biotech Stock Roundup: REGN, SAGE, NMRA Down on Updates, ITCI Gains on Study Success
- Apr 18th, 2024 5:55 pm
Neumora (NMRA) Down on FDA Clinical Hold on Neurology Drug
- Apr 16th, 2024 3:28 pm
Neumora Stock Hits 2024 Low As Side Effects In Rabbits Torpedo Schizophrenia Drug
- Apr 15th, 2024 8:20 pm
Why Is Neurology Focused-Neumora Therapeutics Shares Trading Lower On Monday?
- Apr 15th, 2024 4:17 pm
Neumora’s schizophrenia drug hit with clinical hold
- Apr 15th, 2024 11:47 am
Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study
- Apr 15th, 2024 10:30 am
institutional investors of Neumora Therapeutics, Inc. (NASDAQ:NMRA) must be disappointed after last week's 20% drop
- Mar 14th, 2024 11:37 am
Neumora Therapeutics to Participate at Stifel 2024 Virtual CNS Days
- Mar 13th, 2024 11:00 am
Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Mar 7th, 2024 12:00 pm
Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer
- Jan 22nd, 2024 12:00 pm
Why Neumora Therapeutics (NMRA) Stock Might be a Great Pick
- Jan 10th, 2024 1:32 pm
Neumora Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
- Jan 2nd, 2024 12:00 pm
7 Stocks with Strong Insider Buying: December 2023
- Dec 17th, 2023 5:35 pm
Neumora Therapeutics Appoints Jason Duncan as Chief Legal Officer
- Dec 12th, 2023 12:00 pm
Neumora Therapeutics Announces NMRA-266 IND Clearance and Initiation of Phase 1 Clinical Study
- Nov 27th, 2023 12:00 pm
Neumora Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
- Nov 1st, 2023 11:00 am
Neumora Therapeutics to Participate in Upcoming Conferences in November
- Oct 30th, 2023 11:00 am
Neumora Therapeutics Announces Appointment of Robert Lenz, M.D., Ph.D., as Executive Vice President, Head of Research and Development
- Oct 10th, 2023 11:00 am
Ticking Time Bombs: 3 New Stocks to Dump Before the Damage Is Done (IPO)
- Sep 28th, 2023 11:54 pm
Scroll